afovirsen sodium: a phosphorothioate oligodeoxynucleotide; 20 nucleotides in length; base sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 71587499 |
| MeSH ID | M0225655 |
| Synonym |
|---|
| 138330-98-0 |
| i 2105 |
| thymidine, 2'-deoxy-p-thiocytidylyl-(5'-3')-p-thiothymidylyl-(5'-3')-2'-deoxy-p-thioguanylyl-(5'-3')-2'-deoxy-p-thiocytidylyl-(5'-3')-p-thiothymidylyl-(5'-3')-2'-deoxy-p-thiocytidylyl-(5'-3')-2'-deoxy-p-thiocytidy |
| afovirsen sodium |
| ip 2105 |
| isis 2105 |
| afovirsen sodium [usan] |
| 7el4k2k27p , |
| ip-2105 |
| unii-7el4k2k27p |
| isis-2105 |
| i-2105 |
| DTXSID50160582 |
Afovirsen sodium is a 20-mer phosphorothioate oligonucleotide. It is complementary to the messenger ribonucleic acid sequence for the translation initiation codon of the E2 protein vital to replication of human papillomaviruses 6 and 11.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Afovirsen sodium is a 20-mer phosphorothioate oligonucleotide designed to be complementary to the messenger ribonucleic acid sequence for the translation initiation codon of the E2 protein vital to replication of human papillomaviruses types 6 and 11. " | ( A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Barr, WH; Crooke, ST; Fratkin, MJ; Garrett, A; Grillone, LR; Leeds, J; Tendolkar, A, 1994) | 1.99 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Comparison of these results with those obtained in vivo suggests that the pharmacokinetic behavior of this class of compounds cannot necessarily be predicted from in vitro studies." | ( In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. Cooke, ME; Crooke, RM; Crooke, ST; Graham, MJ, 1995) | 0.29 |
| " From the clinical pharmacokinetic data presented here and from previously published pharmacokinetic data in rats, the disposition of afovirsen in humans appears to be relatively similar to that in rats." | ( A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Barr, WH; Crooke, ST; Fratkin, MJ; Garrett, A; Grillone, LR; Leeds, J; Tendolkar, A, 1994) | 0.55 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " These data suggest that once or twice weekly dosing regimen in the clinic may be appropriate." | ( A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Barr, WH; Crooke, ST; Fratkin, MJ; Garrett, A; Grillone, LR; Leeds, J; Tendolkar, A, 1994) | 0.55 |
| ") dosing of ISIS 2105, a 20-base phosphorothioate oligonucleotide, in timed-pregnant Sprague-Dawley rats." | ( Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion. de Peyster, A; Geary, R; Levin, AA; Riley, JP; Soucy, NV; Templin, MV, 2006) | 0.33 |
| " This dosing regime is higher than a patient would be expected to receive in the clinical use of oligonucleotides." | ( Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion. de Peyster, A; Geary, R; Levin, AA; Riley, JP; Soucy, NV; Templin, MV, 2006) | 0.33 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||